Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
M-M-R II + Varivax refers to the concomitant administration of two live attenuated virus vaccines—M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) and Varivax (Varicella Virus Vaccine Live). Both are administered as separate injections but may be given during the same visit. - **M-M-R II** contains live attenuated strains of measles (Edmonston strain), mumps (Jeryl Lynn strain), and rubella (Wistar RA 27/3 strain) viruses. It induces immunity by stimulating the production of neutralizing antibodies against these viruses[1][7]. - **Varivax** contains a live attenuated Oka/Merck varicella-zoster virus. It induces immunity by stimulating an immune response that protects against chickenpox[8]. Both vaccines are indicated for active immunization in individuals 12 months of age or older to prevent their respective diseases. The mechanism of action is immune system activation via exposure to weakened forms of each virus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on M-M-R II + Varivax.